214 studies found
Biopsies from one of four anatomic locations, from healthy controls and treated (with non-biologic standard of care) or untreated CD patients.
Peripheral blood samples were obtained at week 0 and week 4 of tocilizumab treatment and global gene expression profiling identified markers of responder status.
8 Rheurmatoid arthritis patients have been compared just before and after Leukocytapheresis treatment (overall 16 samples). The Pre-LCAP samples were labeled using Cy5, and the Post-LCAP labeled with Cy3.
mRNA samples were collected from circulating CD4+ and CD8+ T-cells from healthy donors as well as donors with severe and non-severe asthma.
NHEK were treated with IL-19, IL20, IL-22, and IL24, with controls untreated, along with IL1b, IFN gamma, and KGF.
Interim analysis. Study outline is available in Diabetologia (2014) 57:1132–1142.
Twelve whole-blood DNA samples from six SLE patients and six controls were analyzed by Illumina HumanMethylation27 BeadChip.